Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic
Open Access
- 15 July 2021
- journal article
- review article
- Published by MDPI AG in Nanomaterials
- Vol. 11 (7), 1841
- https://doi.org/10.3390/nano11071841
Abstract
The SARS-CoV-2 outbreak is the COVID-19 disease, which has caused massive health devastation, prompting the World Health Organization to declare a worldwide health emergency. The corona virus infected millions of people worldwide, and many died as a result of a lack of particular medications. The current emergency necessitates extensive therapy in order to stop the spread of the coronavirus. There are various vaccinations available, but no validated COVID-19 treatments. Since its outbreak, many therapeutics have been tested, including the use of repurposed medications, nucleoside inhibitors, protease inhibitors, broad spectrum antivirals, convalescence plasma therapies, immune-modulators, and monoclonal antibodies. However, these approaches have not yielded any outcomes and are mostly used to alleviate symptoms associated with potentially fatal adverse drug reactions. Nanoparticles, on the other hand, may prove to be an effective treatment for COVID-19. They can be designed to boost the efficacy of currently available antiviral medications or to trigger a rapid immune response against COVID-19. In the last decade, there has been significant progress in nanotechnology. This review focuses on the virus’s basic structure, pathogenesis, and current treatment options for COVID-19. This study addresses nanotechnology and its applications in diagnosis, prevention, treatment, and targeted vaccine delivery, laying the groundwork for a successful pandemic fight.This publication has 173 references indexed in Scilit:
- A biomimetic nanosponge that absorbs pore-forming toxinsNature Nanotechnology, 2013
- New treatments for influenzaBMC Medicine, 2012
- Development of a new hydrogen peroxide–based vaccine platformNature Medicine, 2012
- Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1Antiviral Research, 2011
- Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cellsProceedings of the National Academy of Sciences of the United States of America, 2010
- Nanoparticle-based targeted drug deliveryExperimental and Molecular Pathology, 2009
- Label-Free, Electrical Detection of the SARS Virus N-Protein with Nanowire Biosensors Utilizing Antibody Mimics as Capture ProbesACS Nano, 2009
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to ClinicCritical Reviews in Therapeutic Drug Carrier Systems, 2009
- Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal ImmunizationJournal of Virology, 2008
- Operational Feasibility of Using Loop-Mediated Isothermal Amplification for Diagnosis of Pulmonary Tuberculosis in Microscopy Centers of Developing CountriesJournal of Clinical Microbiology, 2007